PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 0.7%
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 0.7%
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating) traded down 0.7% during mid-day trading on Wednesday . The stock traded as low as $2.93 and last traded at $2.96. 33,345 shares traded hands during mid-day trading, an increase of 278% from the average session volume of 8,831 shares. The stock had previously closed at $2.98.
Pharmacyte Biotech Inc（OTCMKTS: PMCBD — 獲取評級）在週三午盤交易中下跌了0.7％。該股交易價格低至2.93美元，最後一次交易價格爲2.96美元。在午盤交易中，有33,345股交易，較8,831股的平均交易量增長了278％。該股此前收於2.98美元。
PharmaCyte Biotech Stock Performance
Pharmacyte Biot
The company's 50 day moving average price is $2.93 and its 200-day moving average price is $2.90.
該公司的50天移動平均價格爲2.93美元，其200天移動平均線價格爲2.90美元。
About PharmaCyte Biotech
關於 Pharmacyte
(Get Rating)
（獲取評級）
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Pharmacyte Biotech, Inc是一家臨床階段的生物技術公司，從事癌症和糖尿病治療的開發和商業化。它專注於一種名爲Cell-in-a-box的基於纖維素的專有活細胞封裝技術，該技術將用作開發無法手術的胰腺癌和其他實體癌腫瘤以及糖尿病治療的平臺。
Featured Articles
精選文章
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
- 免費獲取 StockNews.com 關於 Pharmacyte Biotech (PMCBD) 的研究報告的副本
- ASML報告了大規模增長，管理層指出2023年表現疲軟
- 分析師 Boost 會讓洛克希德·馬丁公司的股價上漲、上漲和下跌嗎？
- Mullen Automotive：是玫瑰花的嗎？
- 多元化的雅培實驗室可能會逆轉並走高
- 催化劑接近時Okta的逆轉正在進行中
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Pharmacyte 生物技術日報的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Pharmacyte Biotech及相關公司的最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
